Matching articles for "heart failure"
In Brief: A New Torsemide Formulation (Soaanz) for Edema (online only)
The Medical Letter on Drugs and Therapeutics • August 19, 2024; (Issue 1709)
The FDA has approved Soaanz (Sarfez), a new
formulation of the loop diuretic torsemide, for
treatment of edema associated with heart failure or
renal disease in adults. Torsemide has been...
The FDA has approved Soaanz (Sarfez), a new
formulation of the loop diuretic torsemide, for
treatment of edema associated with heart failure or
renal disease in adults. Torsemide has been available
generically for years for treatment of hypertension and
treatment of edema due to heart failure, renal disease,
or hepatic disease. According to the manufacturer,
Soaanz tablets are formulated to provide a gradual
and sustained diuresis, lowering the risk of excessive
urination and hypokalemia.
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • February 5, 2024; (Issue 1695)
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Sotagliflozin (Inpefa) for Heart Failure
The Medical Letter on Drugs and Therapeutics • July 24, 2023; (Issue 1681)
The FDA has approved sotagliflozin (Inpefa –
Lexicon), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization for heart failure (HF), urgent HF visits,
and...
The FDA has approved sotagliflozin (Inpefa –
Lexicon), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization for heart failure (HF), urgent HF visits,
and cardiovascular death in adults with either HF
(with any left ventricular ejection fraction [LVEF]) or
type 2 diabetes, chronic kidney disease (CKD), and
other cardiovascular risk factors. Sotagliflozin is
the first dual SGLT1/2 inhibitor to be approved in the
US. Unlike SGLT2 inhibitors, it is not FDA-approved
to improve glycemic control in adults with type 2
diabetes. Sotagliflozin is approved in the European
Union as Zynquista for adjunctive treatment of type
1 diabetes.
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure (HF) in adults with heart failure with reduced
ejection fraction (HFrEF). The indication has now
been expanded to include a reduction in the risk
of urgent HF visits and use in adults with any left
ventricular ejection fraction (LVEF).
In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
The Medical Letter on Drugs and Therapeutics • January 23, 2023; (Issue 1668)
The FDA has approved Furoscix (scPharmaceuticals),
a subcutaneous formulation of the loop diuretic
furosemide administered via a single-use, on-body
infusor, for treatment of congestion due to...
The FDA has approved Furoscix (scPharmaceuticals),
a subcutaneous formulation of the loop diuretic
furosemide administered via a single-use, on-body
infusor, for treatment of congestion due to fluid
overload in adults with New York Heart Association
(NYHA) Class II-III chronic heart failure (HF).
Furosemide (Lasix, and generics) has been available
for years in oral and IV formulations.
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • June 13, 2022; (Issue 1652)
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
The Medical Letter on Drugs and Therapeutics • April 18, 2022; (Issue 1648)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
was approved by the FDA in 2021 to reduce the
risk of hospitalization for heart failure (HF)...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
was approved by the FDA in 2021 to reduce the
risk of hospitalization for heart failure (HF) and
cardiovascular death in patients with heart failure
with reduced ejection fraction (HFrEF; LVEF ≤40%),
regardless of whether or not they have type 2
diabetes. The indication has now been expanded to
include patients with HF with any ejection fraction.
Empagliflozin is the first SGLT2 inhibitor to be
approved in the US for this indication.
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
The Medical Letter on Drugs and Therapeutics • November 1, 2021; (Issue 1636)
The FDA has approved an expansion of the
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a...
The FDA has approved an expansion of the
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a lower extremity revascularization
procedure for symptomatic PAD (see Table 1).
Rivaroxaban is the first direct oral anticoagulant
(DOAC) to be approved for use in patients with PAD.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • June 14, 2021; (Issue 1626)
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication
The Medical Letter on Drugs and Therapeutics • May 3, 2021; (Issue 1623)
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of...
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of cardiovascular
death and hospitalization for heart failure in adults with
chronic heart failure (NYHA Class II-IV) and reduced
ejection fraction (HFrEF; LVEF <40%). The FDA has
now expanded its indication to include patients with
chronic heart failure with any LVEF; the label specifies
that benefits are most clearly evident in patients with
LVEF below normal. Entresto is the first drug to be
approved in the US for this indication.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension and
chronic thromboembolic pulmonary hypertension,
was the first.
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
...
View the Comparison Table: Some Drugs for HFrEF
Empagliflozin (Jardiance) for Heart Failure
The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)
In a randomized, placebo-controlled trial, the
sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly)
reduced the composite risk of cardiovascular death
or...
In a randomized, placebo-controlled trial, the
sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly)
reduced the composite risk of cardiovascular death
or hospitalization for worsening heart failure (HF)
in patients with heart failure with reduced ejection
fraction (HFrEF), whether or not they had type 2
diabetes. To date, empagliflozin has not been
approved by the FDA for such use. The SGLT2 inhibitor
dapagliflozin (Farxiga) was approved by the FDA for
this indication earlier this year.
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
The Medical Letter on Drugs and Therapeutics • June 29, 2020; (Issue 1601)
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease
(CVD) or multiple cardiovascular risk factors, has
now been approved for a third indication: to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in patients with heart failure
with reduced ejection fraction (with or without
type 2 diabetes). It is the first SGLT2 inhibitor to be
approved in the US for this indication.
Correction: Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • July 1, 2019; (Issue 1575)
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor...
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as "suboptimal". Some readers have objected to that characterization.
The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce mortality in patients with HFrEF.2 In the trial, the rate of death from cardiovascular causes or hospitalization for heart failure was significantly lower with the combination of valsartan and sacubitril than with enalapril 10 mg twice daily (21.8% vs 26.5%). Whether allowing titration to 20 mg twice daily would have changed that result is a reasonable question, but there is no direct evidence that the higher dosage is more effective for this indication.3 We have removed the word "suboptimal" from the article as it appears online.
Download complete U.S. English article
The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce mortality in patients with HFrEF.2 In the trial, the rate of death from cardiovascular causes or hospitalization for heart failure was significantly lower with the combination of valsartan and sacubitril than with enalapril 10 mg twice daily (21.8% vs 26.5%). Whether allowing titration to 20 mg twice daily would have changed that result is a reasonable question, but there is no direct evidence that the higher dosage is more effective for this indication.3 We have removed the word "suboptimal" from the article as it appears online.
- Med Lett Drugs Ther 2019; 61:49.
- JJ McMurray et al. N Engl J Med 2014; 371:993.
- N Bartell and WH Frishman. Cardiol Rev 2017; 25:315.
Download complete U.S. English article
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are...
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are considered to have
heart failure with preserved ejection fraction (HFpEF).
There is little evidence that drug treatment improves
clinical outcomes in patients with HFpEF.
Expanded Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
...
View the Expanded Table: Some Drugs for HFrEF
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Byvalson - A Beta Blocker/ARB Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • September 12, 2016; (Issue 1503)
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment...
The FDA has approved Byvalson (Allergan), a fixed-dose
combination of the beta blocker nebivolol
(Bystolic) and the angiotensin receptor blocker (ARB)
valsartan (Diovan, and generics), for treatment of
hypertension. It is the only combination product that
contains nebivolol, and the first to combine a beta
blocker with an ARB.
Sacubitril/Valsartan (Entresto) for Heart Failure
The Medical Letter on Drugs and Therapeutics • August 3, 2015; (Issue 1474)
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular...
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular death
and heart failure hospitalization in patients with
heart failure with reduced ejection fraction. Sacubitril
is the first neprilysin inhibitor to become available in
the US.
Ivabradine (Corlanor) for Heart Failure
The Medical Letter on Drugs and Therapeutics • May 25, 2015; (Issue 1469)
The FDA has approved ivabradine (Corlanor – Amgen)
to reduce the risk of hospitalization for worsening heart
failure in adults with stable, symptomatic chronic heart
failure with left ventricular ejection...
The FDA has approved ivabradine (Corlanor – Amgen)
to reduce the risk of hospitalization for worsening heart
failure in adults with stable, symptomatic chronic heart
failure with left ventricular ejection fraction (LVEF) ≤35%
who are in sinus rhythm with a resting heart rate ≥70
beats per minute and who are on maximum tolerated
doses of beta blockers or have a contraindication
to beta blocker use. Ivabradine has been available
internationally for years as Procoralan and Corlentor
for treatment of stable angina and heart failure.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure...
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF) or systolic heart failure. Patients
with a LVEF ≥50% and symptoms of heart failure
are considered to have heart failure with preserved
ejection fraction (HFpEF) or diastolic heart failure;
there is little evidence that drug treatment improves
clinical outcomes in these patients. The treatment of
acute heart failure is not included here.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • September 1, 2012; (Issue 121)
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no...
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no evidence that
drug treatment of heart failure with preserved systolic
function (LVEF >40%) improves clinical outcomes.
Some of the drugs commonly used now for treatment of
chronic heart failure are listed in the table on page 71.
In Brief: Nesiritide (Natrecor)
The Medical Letter on Drugs and Therapeutics • November 14, 2011; (Issue 1377)
A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001...
A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001 (conditionally approved by Health Canada in 2007) for relief of dyspnea in patients with acutely decompensated heart failure. The authors of the recent clinical trial concluded: "On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure."1 The editorialist lamented the inadequacy of the data that had led to the approval of the drug in the first place, the 10 years of "fuzziness and ambiguity" that had followed regarding its use, and the "more than $1 billion" wasted on buying it.2
In 2001, when nesiritide was first approved in the US, The Medical Letter also expressed dissatisfaction with the quality of the data criticized by the 2011 editorialist, and concluded its assessment of nesiritide as follows: "Until more published data become available, nesiritide should probably be reserved for treatment of patients with heart failure who have not responded to nitroglycerin and cannot be treated with nitroprusside."3
1. CM O’Connor et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32.
2. EJ Topol. The lost decade of nesiritide. N Engl J Med 2011; 365:81.
3. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001; 43:100.
Download U.S. English
In 2001, when nesiritide was first approved in the US, The Medical Letter also expressed dissatisfaction with the quality of the data criticized by the 2011 editorialist, and concluded its assessment of nesiritide as follows: "Until more published data become available, nesiritide should probably be reserved for treatment of patients with heart failure who have not responded to nitroglycerin and cannot be treated with nitroprusside."3
1. CM O’Connor et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32.
2. EJ Topol. The lost decade of nesiritide. N Engl J Med 2011; 365:81.
3. Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001; 43:100.
Download U.S. English
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 1, 2010; (Issue 97)
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals...
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Drugs for Treatment of Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • July 1, 2009; (Issue 83)
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as...
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
A Diuretic for Initial Treatment of Hypertension?
The Medical Letter on Drugs and Therapeutics • February 9, 2009; (Issue 1305)
Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be...
Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be controversial.
Nebivolol (Bystolic) for Hypertension
The Medical Letter on Drugs and Therapeutics • March 10, 2008; (Issue 1281)
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Coenzyme Q10
The Medical Letter on Drugs and Therapeutics • February 27, 2006; (Issue 1229)
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • January 1, 2006; (Issue 41)
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the...
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
BiDil for Heart Failure
The Medical Letter on Drugs and Therapeutics • September 28, 2005; (Issue 1218)
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral...
BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • April 1, 2003; (Issue 8)
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as...
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19.
Nesiritide For Decompensated Congestive Heart Failure
The Medical Letter on Drugs and Therapeutics • November 12, 2001; (Issue 1118)
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or...
Nesiritide, a recombinant human B-type natriuretic peptide (BNP), has been approved by the FDA of intravenous (IV) treatment of patients with decompensated congestive heart failure who have dyspnea at rest or with minimal exertion (New York Heart Association class IV).
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 29, 1999; (Issue 1045)
...
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • October 11, 1996; (Issue 985)
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on...
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 14, 1993; (Issue 896)
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs...
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs that decrease cardicac preload and afterload and those that increase contractility are commonly used together.
Flosequinan for Heart Failure
The Medical Letter on Drugs and Therapeutics • March 19, 1993; (Issue 892)
Flosequinan (Manoplax - Boots), a fluoroquinolone derivative, is now available in the USA for treatment of congestive heart failure. Labeling approved by the US Food and Drug Administration recommends the...
Flosequinan (Manoplax - Boots), a fluoroquinolone derivative, is now available in the USA for treatment of congestive heart failure. Labeling approved by the US Food and Drug Administration recommends the drug only for patients who cannot tolerate or have not responded adequately to an angiotensin-converting enzyme (ACE) inhibitor.
Lisinopril For Hypertension
The Medical Letter on Drugs and Therapeutics • April 8, 1988; (Issue 763)
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors,...
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril (Capoten - Squibb) and e